FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

The US FDA approved daraxonrasib, a first-in-class daily oral RAS inhibitor, for metastatic pancreatic adenocarcinoma patients who have had prior systemic therapy or are ineligible for multiagent systemic treatment, offering a chemotherapy-free targeted therapy that doubles survival.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.